NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES

Date
2010
Author
Nalcaci, Meliha
Bayrak, Ayseguel
Ucur, Ali
Yenerel, Mustafa Nuri
Akpinar, Timur
Cefle, Kivanc
Palanduz, Suekrue
Elcioglu, Oemer Celal
Yavuz, Akif Selim
Oeztuerk, Suekrue
Aktan, Melih
Cosan, Fulya
Metadata
Show full item record
Abstract
Objective: Clonal cytogenetic aberrations other than Philadelphia chromosome can develop during the course of chronic myeloid leukemia naturally or under the pressure of treatment strategies like interferon, imatinib and dasatinib. Some of them are associated with resistance to treatment and progression to advanced phases of chronic myeloid leukemia. Nilotinib is a second generation thyrosine kinase inhibitor, but its efficacy in chronic myeloid leukemia patients with additional chromosomal changes has not been delineated yet. In this study we evaluated the efficacy of nilotinib in imatinib-resistant or -intolerant t(9;22) positive chronic myeloid leukemia patients with and without additional chromosomal changes
URI
http://hdl.handle.net/20.500.12627/41194
Collections